Reumofan Induced Edema

Apurva Akkad, Justin K. Lui, Sandra Tirrell


We are presenting a first ever published report in the English literature in a patient presenting with adverse effects of an FDA-banned medicine, Reumofan, which has been marketed to treat rheumatism, joint pain, arthritis and neuralgia. It contains undisclosed traces of dexamethasone, diclofenac and methocarbamol. Some of these adverse effects include hypertension, adrenal insufficiency, gastrointestinal bleeding and sudden death. Our patient presented with progressively worsening edema affecting upper and lower extremities, abdominal wall and face. He was ruled out for venous thrombosis, and his cardiac catheterization and transthoracic echocardiogram exhibited no evidence of heart failure. His edema was successfully treated with diuresis during his hospitalization and on follow-up visit, he was found to be adrenally insufficient and hypotensive on discontinuation of Reumofan. This case illustrates the severe adverse effects that can occur as a result of Reumofan use in a patient using this medicine to treat debilitating joint pain and reinforces the importance of a thorough medication history.

J Endocrinol Metab. 2014;4(3):78-80


Reumofan; Edema; Drug toxicity

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.